D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia (Q33845745)

29 July 2017

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia (English)

1 reference

29 July 2017

0 references

1 reference

1 reference

5

Donald C Goff

1 reference

29 July 2017

A Eden Evins

1

1 reference

29 July 2017

Ed Amico

series ordinal

2

1 reference

29 July 2017

Thomas A Posever

series ordinal

3

1 reference

29 July 2017

Rob Toker

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

29 July 2017

Schizophrenia Research

1 reference

29 July 2017

56

1 reference

29 July 2017

1-2

1 reference

29 July 2017

19-23

1 reference

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900220-1

7 January 2021

10.1016/S0920-9964(01)00220-1

Identifiers

DOI

1 reference

release_zbwbqv7qovf4tc3frjekjclq2a

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zbwbqv7qovf4tc3frjekjclq2a

24 November 2022

mapped directly with Wikidata item

1 reference